Pharmaceutical Investing CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
Pharmaceutical Investing Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
Pharmaceutical Investing PADCEV Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pharmaceutical Investing Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
Pharmaceutical Investing Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
Pharmaceutical Investing TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
Pharmaceutical Investing Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
Pharmaceutical Investing CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual Meeting
Pharmaceutical Investing AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
